Browsing Tag
CBT-004
2 posts
Why pinguecula drug development is gaining momentum after Cloudbreak Pharma’s FDA discussions
Find out why Cloudbreak Pharma’s FDA discussions are changing how investors and regulators view pinguecula drug development and late-stage ophthalmology risk.
Cloudbreak Pharma announces positive clinical results for vascularized pinguecula therapy
CBT-004 shows significant efficacy and safety in Phase 2 trial for vascularized pinguecula; experts cite breakthrough in non-steroidal treatment.